Chief Science Officer Dr. Maria C. Carrillo shares how topline positive results seen in drug trials like lecanemab will change the way we treat Alzheimer’s. While full data is not yet available, this initial readout brings hope for a future where people living in the early stages of Alzheimer's have #moretime. Read more on alz.org/blog.